Sequence information
Variant position: 96 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 110 The length of the canonical sequence.
Location on the sequence:
SLQPLALEGSLQKRGIVEQC
C TSICSLYQLENYCN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human SLQPLALEGSLQKRGIVEQCC TSICSLYQLENYCN
Gorilla SLQPLALEGSLQKRGIVEQCC TSICSLYQLENYCN
GLQPLALEGALQKRGIVEQCC TSICSLYQLENYCN
Chimpanzee SLQPLALEGSLQKRGIVEQCC TSICSLYQLENYCN
Pig GLQALALEGPPQKRGIVEQCC TSICSLYQLENYCN
Bovine GL-----EGPPQKRGIVEQCC ASVCSLYQLENYCN
Rabbit GLQPSALELALQKRGIVEQCC TSICSLYQLENYCN
Goat --------------GIVEQCC AGVCSLYQLENYCN
Sheep GL-----EGPPQKRGIVEQCC AGVCSLYQLENYCN
Cat GLQPSALEAPLQKRGIVEQCC ASVCSLYQLEHYCN
Horse GLQPLALAGPQQXXGIVEQCC TGICSLYQLENYCN
Chicken VLPFQQEEYEKVKRGIVEQCC HNTCSLYQLENYCN
Zebrafish DFAFKDHAELIRKRGIVEQCC HKPCSIFELQNYCN
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Peptide
90 – 110
Insulin A chain
Disulfide bond
31 – 96
Interchain (between B and A chains)
Disulfide bond
43 – 109
Interchain (between B and A chains)
Disulfide bond
95 – 100
Helix
91 – 97
Literature citations
Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.
Edghill E.L.; Flanagan S.E.; Patch A.M.; Boustred C.; Parrish A.; Shields B.; Shepherd M.H.; Hussain K.; Kapoor R.R.; Malecki M.; MacDonald M.J.; Stoy J.; Steiner D.F.; Philipson L.H.; Bell G.I.; Hattersley A.T.; Ellard S.;
Diabetes 57:1034-1042(2008)
Cited for: VARIANTS PNDM4 ASP-24; ASP-29; ARG-32; SER-32; PRO-35; GLY-43; VAL-47; CYS-48; ARG-84; CYS-89; CYS-90; SER-96; TYR-96; CYS-101; CYS-103 AND CYS-108; VARIANT MODY10 CYS-6; VARIANT MET-68;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.